Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)
Clin. transl. oncol. (Print)
; 18(8): 769-775, ago. 2016. tab, graf
Article
en En
| IBECS
| ID: ibc-154051
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Background:
Of all thyroid cancers,< 5 % are medullary (MTC). It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny.Methods:
The electronic search was conducted using MEDLINE (PubMed), EMBASE and Cochrane Central Register of Controlled Trials. Quality assessments of selected current articles, guidelines and reviews of MTC were performed.Results:
This consensus updates and summarizes biology, treatment and prognostic considerations of MTC.Conclusions:
Multidisciplinary teams and specialized centers are recommended for the management of MTC patients. In the metastatic setting, those patients with large volume of disease are candidates to start systemic treatment mainly if they are symptomatic and the tumor has progressed in the last 12-14 months. Wait and see strategy should be offered to patients with disseminated disease with only high levels of calcitonin and no macroscopic structural disease, low burden and absence of progression (AU)RESUMEN
No disponible
Buscar en Google
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Pronóstico
/
Neoplasias de la Tiroides
/
Conferencias de Consenso como Asunto
/
Carcinoma Anaplásico de Tiroides
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2016
Tipo del documento:
Article